Advisor and Founder

Chief Commercial Officer

Regulatory actions for June 6, 2025

EC approves Santen’s Ryjunea to slow progression of pediatric myopia

EC approves Santen’s Ryjunea to slow progression of paediatric myopia

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Head of Pharmacovigilance

Sydnexis Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for pediatric eye health. The Head of Pharmacovigilance will lead the operational activities of pharmacovigilance, ensuring compliance with regulatory requirements and managing safety reports for products in clinical development.

Sign up with Google

Sign in with Google